美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

OncoMed Pharmaceuticals, Inc.

0.8900

0.0000

成交量：- -

成交额：- -

市值：3,443.42万

市盈率：-4.22

高：0.8900

开：0.8900

低：0.8900

收：0.8900

52周最高：3.35

52周最低：0.5467

股本：3,869.01万

流通股本：2,608.64万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.2107

每股收益(LYR):-0.2107

净资产收益率：--

总资产收益率：--

市净率：0.71

市盈率(LYR):-4.22

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

OncoMed Pharmaceuticals, Inc.

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.oncomed.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Oncomed Pharmaceuticals, Inc.作为一家临床阶段的生物技术公司于2004年7月在特拉华州成立。公司致力于发现和开发对抗肿瘤干细胞的类单克隆抗体药物。公司的业务和工作地点位于加利福尼亚州红木城。其候选产品的目标是干细胞自我更新和通过阻断肿瘤干细胞和大部分肿瘤细胞，以驱动细胞向非致瘤性状态分化。公司认为，其候选产品不同于目前的化疗，有显著影响癌症治疗与临床结果的可能。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/OMED/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","market":"US","secType":"STK","nameCN":"OncoMed Pharmaceuticals, Inc.","latestPrice":0.89,"timestamp":1557432000000,"preClose":0.89,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":26086382,"shares":38690089,"eps":-0.210727,"marketStatus":"停牌","change":0,"latestTime":"05-09 16:00:00 EDT","open":0.89,"high":0.89,"low":0.89,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.210727,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1374120000000,"exchange":"NASDAQ","adjPreClose":0.89,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OMED\",,,,,undefined,":{"symbol":"OMED","floatShares":26086382,"roa":"--","roe":"--","lyrEps":-0.210727,"shares":38690089,"dividePrice":0,"high":0.89,"amplitude":0,"preClose":0.89,"low":0.89,"week52Low":0.5467,"pbRate":"0.71","week52High":3.35,"institutionHeld":0,"latestPrice":0.89,"eps":-0.210727,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.210727,"open":0.89,"prevYearClose":0.89},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OMED\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-07","symbol":"OMED","fiscalQuarterEnding":"2018/12","expectedEps":-0.22,"name":null,"time":"","type":"earning","dateTimestamp":1551934800000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2018-11-01","symbol":"OMED","fiscalQuarterEnding":"2018/09","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1541044800000,"reportTimeType":"","actualEps":0.16},{"market":"US","date":"2018-08-02","symbol":"OMED","fiscalQuarterEnding":"2018/06","expectedEps":-0.23,"name":null,"time":"","type":"earning","dateTimestamp":1533182400000,"reportTimeType":"","actualEps":-0.1},{"market":"US","date":"2018-05-08","symbol":"OMED","fiscalQuarterEnding":"2018/03","expectedEps":-0.25,"name":null,"time":"盘后","type":"earning","dateTimestamp":1525752000000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2018-03-08","symbol":"OMED","fiscalQuarterEnding":"2017/12","expectedEps":-0.31,"name":null,"time":"盘后","type":"earning","dateTimestamp":1520485200000,"reportTimeType":"post","actualEps":0.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OMED\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.oncomed.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Oncomed Pharmaceuticals, Inc.作为一家临床阶段的生物技术公司于2004年7月在特拉华州成立。公司致力于发现和开发对抗肿瘤干细胞的类单克隆抗体药物。公司的业务和工作地点位于加利福尼亚州红木城。其候选产品的目标是干细胞自我更新和通过阻断肿瘤干细胞和大部分肿瘤细胞，以驱动细胞向非致瘤性状态分化。公司认为，其候选产品不同于目前的化疗，有显著影响癌症治疗与临床结果的可能。","exchange":"NASDAQ","name":"OncoMed Pharmaceuticals, Inc.","nameEN":"OncoMed Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OMED\",market:\"US\",,,undefined,":null}}